COVID-19 vaccine-associated mortality in the Southern Hemisphere

By Denis G. Rancourt, Marine Baudin, Joseph Hickey, Jérémie Mercier

Citation: Rancourt, D.G., Baudin, M., Hickey, J., Mercier, J. “COVID-19 vaccine-associated mortality in the Southern Hemisphere”. CORRELATION Research in the Public Interest, Report, 17 September 2023. https://correlation-canada.org/covid-19-vaccine-associated-mortality-in-the-Southern-Hemisphere/

This is our latest study of all-cause mortality, published today. It is 180 pages. It would take a year to format it for substack. Therefore, here is the Abstract and a few parts. Download the full report.

Abstract

Seventeen equatorial and Southern-Hemisphere countries were studied (Argentina, Australia, Bolivia, Brazil, Chile, Colombia, Ecuador, Malaysia, New Zealand, Paraguay, Peru, Philippines, Singapore, South Africa, Suriname, Thailand, Uruguay), which comprise 9.10 % of worldwide population, 10.3 % of worldwide COVID-19 injections (vaccination rate of 1.91 injections per person, all ages), virtually every COVID-19 vaccine type and manufacturer, and span 4 continents.

In the 17 countries, there is no evidence in all-cause mortality (ACM) by time data of any beneficial effect of COVID-19 vaccines. There is no association in time between COVID-19 vaccination and any proportionate reduction in ACM. The opposite occurs.

All 17 countries have transitions to regimes of high ACM, which occur when the COVID‑19 vaccines are deployed and administered. Nine of the 17 countries have no detectable excess ACM in the period of approximately one year after a pandemic was declared on 11 March 2020 by the World Health Organization (WHO), until the vaccines are rolled out (Australia, Malaysia, New Zealand, Paraguay, Philippines, Singapore, Suriname, Thailand, Uruguay).

Unprecedented peaks in ACM occur in the summer (January-February) of 2022 in the Southern Hemisphere, and in equatorial-latitude countries, which are synchronous with or immediately preceded by rapid COVID-19-vaccine-booster-dose rollouts (3rd or 4th doses). This phenomenon is present in every case with sufficient mortality data (15 countries). Two of the countries studied have insufficient mortality data in January-February 2022 (Argentina and Suriname).

Detailed mortality and vaccination data for Chile and Peru allow resolution by age and by dose number. It is unlikely that the observed peaks in all-cause mortality in January-February 2022 (and additionally in: July-August 2021, Chile; July-August 2022, Peru), in each of both countries and in each elderly age group, could be due to any cause other than the temporally associated rapid COVID-19-vaccine-booster-dose rollouts. Likewise, it is unlikely that the transitions to regimes of high ACM, coincident with the rollout and sustained administration of COVID‑19 vaccines, in all 17 Southern-Hemisphere and equatorial-latitude countries, could be due to any cause other than the vaccines.

Synchronicity between the many peaks in ACM (in 17 countries, on 4 continents, in all elderly age groups, at different times) and associated rapid booster rollouts allows this firm conclusion regarding causality, and accurate quantification of COVID-19-vaccine toxicity.

The all-ages vaccine-dose fatality rate (vDFR), which is the ratio of inferred vaccine-induced deaths to vaccine doses delivered in a population, is quantified for the January-February 2022 ACM peak to fall in the range 0.02 % (New Zealand) to 0.20 % (Uruguay). In Chile and Peru, the vDFR increases exponentially with age (doubling approximately every 4 years of age), and is largest for the latest booster doses, reaching approximately 5 % in the 90+ years age groups (1 death per 20 injections of dose 4). Comparable results occur for the Northern Hemisphere, as found in previous articles (India, Israel, USA).

We quantify the overall all-ages vDFR for the 17 countries to be (0.126 ± 0.004) %, which would imply 17.0 ± 0.5 million COVID-19 vaccine deaths worldwide, from 13.50 billion injections up to 2 September 2023. This would correspond to a mass iatrogenic event that killed (0.213 ± 0.006) % of the world population (1 death per 470 living persons, in less than 3 years), and did not measurably prevent any deaths.

The overall risk of death induced by injection with the COVID-19 vaccines in actual populations, inferred from excess all‑cause mortality and its synchronicity with rollouts, is globally pervasive and much larger than reported in clinical trials, adverse effect monitoring, and cause-of-death statistics from death certificates, by 3 orders of magnitude (1,000‑fold greater).

The large age dependence and large values of vDFR quantified in this study of 17 countries on 4 continents, using all the main COVID-19 vaccine types and manufacturers, should induce governments to immediately end the baseless public health policy of prioritizing elderly residents for injection with COVID-19 vaccines, until valid risk-benefit analyses are made.

[see Results and Discussion…]

7.  Conclusion          

7.1               Causality proven

The 17 countries studied (Argentina, Australia, Bolivia, Brazil, Chile, Colombia, Ecuador, Malaysia, New Zealand, Paraguay, Peru, Philippines, Singapore, South Africa, Suriname, Thailand, Uruguay) comprise 9.10 % of worldwide population, 10.3 % of worldwide COVID-19 injections (vaccination rate of 1.91 injections per person, all ages), virtually every COVID-19 vaccine type and manufacturer, and span 4 continents.

The scientific tests for causality are amply satisfied, as extensively demonstrated in these sections of the present paper:

·         COVID-19 vaccines can cause death

·         Absence of excess mortality until the COVID-19 vaccines are rolled out

·         The COVID-19 vaccines did not save lives and appear to be lethal toxic agents

·         Strong evidence for a causal association and vaccine lethal toxicity

·         Causality in excess mortality is amply demonstrated

·         Assessing other interpretations of the cause of the excess mortality

·         Implications regarding age-dependence of fatal toxicity of COVID-19 vaccines

Also, there are no known facts that disprove the inferred and quantitative causal relation between the observed excess ACM peaks and the temporally associated COVID-19 vaccine and booster rollouts.

7.2               Actual vaccine mortality much larger than that incorrectly inferred from faulty data

There can be little doubt that the peaks in excess ACM are caused by the COVID-19 vaccinations, with a mean all-ages fatal toxicity by injection of vDFR = (0.126 ± 0.004) %, or approximately 1 death per 800 injections, which is reasonably expected to be globally representative.

This is a staggering number, compared to what is generally believed about traditional vaccines, which is approximately one serious adverse effect per million (Malhotra, 2023). It is three orders of magnitude (one thousand times) larger.

In contrast to this large number from ACM data, the effective all-ages vDFR values inferred from other sources — the small number of autopsy confirmations, adverse effect monitoring of deaths, the small number of national vaccine injury compensation payments for deaths, pharmaceutical-industry clinical trial reports, and death-certificates and corresponding government-reported cause-of-death statistics — for COVID-19 vaccines are significantly smaller, again by orders of magnitude.

Therefore, we conclude with a high degree of certainty that adverse-effect monitoring, clinical trial reports, and death-certificate statistics greatly underestimate the fatal toxicity of the injections.

The large gap between incorrectly inferred and actual population-level vDFR values probably occurs because of systemic avoidance of admitting the injections as a possible cause of death in frail and vulnerable patients. For example, the cause(s) of death will be attributed to particular organ or system failures, without reference to the vaccine, even if the injection was recent and the patient was previously stable.

The measured all-ages vDFR of (0.126 ± 0.004) % implies that 17.0 ± 0.5 million COVID‑19 vaccine deaths would have occurred globally, up to 2 September 2023. It appears that the global COVID-19 vaccination campaign was in effect a mass iatrogenic event that killed (0.213 ± 0.006) % of the world population (1 death per 470 living persons, in less than 3 years), and did not measurably prevent any deaths.

7.3               The policy of prioritizing elderly residents for COVID-19 vaccination must be ended

The detailed age and dose-discriminated data for Chile and Peru allows unprecedented certainty in quantifying the age dependence of the fatal toxicity from COVID-19 vaccines. The risk of death per injection (vDFR) increases exponentially with age, for 60+ years ages, doubling approximately every 4 years in age, and attains values of approximately 5 % for 90+ year-olds subjected to dose 4 (2nd booster). vDFR = 5 % corresponds to 1 death per 20 injections of dose 4 for 90+ year-olds.

These vDFR values are consistent with all prior evaluations based on ACM:

·         1 % (1 death per 100 injections) (nominally all ages) in India (Rancourt, 2022)

·         0.55 % (1 death per 180 injections) for 80+ year-olds in Israel (Rancourt et al., 2023; their Table 2)

·         0.93 % (1 death per 110 injections) for 85+ year-olds in Australia (Rancourt et al., 2023; their Table 1)

The population-level age-dependence of vDFR (doubling every 4 years in age) and its large magnitude should induce governments to immediately implement an absolute pause on the baseless public health policy of prioritizing elderly people for injection with COVID‑19 vaccines, until valid risk-benefit analyses are made and publicly reported. The same may be true of seasonal influenza vaccines.

Download the full report.

All my scientific articles about COVID are on my website.

My many research areas are presented here.